The Pharma stocks are positive due to multiple approvals of US FDA for different medicines. The companies are also manufacturing the drugs for the primary treatment of Covid-19. Dr Reddy's Laboratories reclaimed the tag of being the second most valuable listed pharmaceutical company. Sun Pharma is the most valued listed company of India with the market cap of Rs 1.26lakh cr. With a favourable ruling in the appeals court, the odds of launching gVascepa also rise considerably. Bristol Myers Squibb had inked a patent settlement with Dr. Reddy’s Laboratories, allowing the Indian generics company to start with a “volume-limited” launch sometime after March 2022. The exact date of the rollout, and amount of generic Revlimid Dr. Reddy’s will be allowed to sell, are confidential. But on January 31, 2026, the company will have a license to sell its generic Revlimid with no limits. #MOMarketUpdates #IndianStockMarket #MotilalOswal #NiftyPharma #NSE #BSE #Recommendation #Stocktip #Stockrecommendation
Posted On: 18 Sep 2020 5:44 PM
